Form 4: Ultragenyx Executive Receives Equity Compensation

John Richard Pinion, EVP and Chief Quality Operations Officer at Ultragenyx, was granted 23,116 restricted stock units and 79,936 stock options.

Summary

• John Richard Pinion, EVP and Chief Quality Operations Officer, received an equity grant on April 16, 2026.
• The grant includes 23,116 Restricted Stock Units (RSUs) vesting over four years.
• The grant includes 79,936 stock options with an exercise price of $24.52, expiring in 2036.
• Following these transactions, the reporting person holds 133,142 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation, which is neutral for the stock price.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.
• Retention of key leadership personnel in the Chief Quality Operations role.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Vesting conditions are subject to continued employment and performance criteria.
• Market volatility may impact the future value of the granted options and RSUs.

Future Outlook

The equity grants are subject to standard vesting schedules, with RSUs vesting annually over four years and options beginning to vest after one year, followed by monthly vesting.

Management Comments

• The transaction reflects standard executive compensation practices under the Company's 2023 Incentive Plan.

Industry Context

StockSavvy.ai notes that equity-based compensation remains the standard mechanism for aligning executive incentives with long-term corporate performance in the biotechnology sector.

Comparison to Industry Standards

• The use of a four-year vesting schedule for RSUs and options is consistent with standard industry practices for executive retention in mid-cap biotech firms.
• The exercise price of $24.52 aligns with typical grant-date fair market value practices.

Stakeholder Impact

• Shareholders may experience minor dilution from the issuance of new equity.

Next Steps

• Vesting of RSU tranches on annual anniversaries of the grant date.
• Vesting of stock options beginning on the first anniversary of the grant date.

Key Dates

Keywords

Ultragenyx, RARE, Form 4, Insider Trading, Equity Compensation, Executive Compensation